NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2014.

Cover of GeneReviews®

GeneReviews® [Internet].

Show details

Amyotrophic Lateral Sclerosis Overview

Synonym: Lou Gehrig's Disease

, MS, CGC and , MD.

Author Information
, MS, CGC
Division of Neuromuscular Medicine
Davee Department of Neurology and Clinical Neurosciences
Northwestern University Feinberg School of Medicine
Chicago, Illinois
, MD
Division of Neuromuscular Medicine
Davee Department of Neurology and Clinical Neurosciences and the Department of Cell and Molecular Biology
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Initial Posting: ; Last Update: May 31, 2012.

Summary

Disease characteristics. Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease involving both upper motor neurons (UMN) and lower motor neurons (LMN). UMN signs include hyperreflexia, extensor plantar response, increased muscle tone, and weakness in a topographic representation. LMN signs include weakness, muscle wasting, hyporeflexia, muscle cramps, and fasciculations. Initial presentation varies. Affected individuals typically present with either asymmetric focal weakness of the extremities (stumbling or poor handgrip) or bulbar findings (dysarthria, dysphagia). Other findings may include muscle fasciculations, muscle cramps, and labile affect, but not necessarily mood. Regardless of initial symptoms, atrophy and weakness eventually affect other muscles. The mean age of onset is 56 years in individuals with no known family history and 46 years in individuals with more than one affected family member (familial ALS or FALS). Average disease duration is about three years, but it can vary significantly. Death usually results from compromise of the respiratory muscles.

Diagnosis/testing. The diagnosis of ALS is based on clinical features, electrodiagnostic testing, and exclusion of other health conditions with related symptoms. Molecular genetic testing plays a prominent role in diagnosis of the genetic subtype and genetic counseling.

Genetic counseling. Amyotrophic lateral sclerosis can be inherited in an autosomal dominant, autosomal recessive, or X-linked manner. Genetic counseling and risk assessment depend on accurate determination of the specific genetic diagnosis.

Management. Treatment of manifestations: Treatment is palliative. Individuals with ALS may benefit from care by a multidisciplinary team that includes a neurologist, specially trained nurses, pulmonologist, speech therapist, physical therapist, occupational therapist, respiratory therapist, nutritionist, psychologist, social worker, and genetics professional. Riluzole is the only currently FDA-approved drug for treatment of ALS. Oral secretions in those with bulbar symptoms can be reduced with tricylic antidepressants and other anticholinergic agents. Pseudobulbar affect can be managed with antidepressants. Swallowing difficulties can be alleviated by thickening liquids and pureeing solid food and, eventually, by use of a gastrostomy tube to help maintain caloric intake and hydration. Medications such as baclofen and benzodiazepines can help relieve spasticity and muscle cramps. Alphabet boards and computer-assisted devices can aid communication. Other assistive devices such as walkers, wheelchairs, bathroom modifications, hospital beds, and Hoyer lifts can aid in activities of daily life. Ventilatory assistance may include BIPAP and/or mechanical ventilation. Hospice care in terminal stages is beneficial.

Definition

Clinical Manifestations of ALS

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease involving both upper motor neurons (UMNs) and lower motor neurons (LMNs). Upper motor neurons, located in the motor cortex of the frontal lobe, send their axons through the great corticofugal tracts to the brain stem (corticobulbar neurons) and the spinal cord (corticospinal neurons) to influence patterned activity of the lower motor neurons (LMS). Additional UMN influences on the LMN are carried over descending pathways of the brain stem. UMN signs in ALS include hyperreflexia, extensor plantar response, and increased muscle tone. Lower motor neurons, located in the brain stem and spinal cord, innervate striated muscle. LMN signs in ALS include weakness, muscle wasting (atrophy), hyporeflexia, muscle cramps, and fasciculations.

Disease characteristics. Symptoms present in early disease may vary. Affected individuals most often present with either asymmetric focal weakness of the extremities (stumbling or poor handgrip) or bulbar findings (dysarthria, dysphagia). Other findings may include muscle fasciculations, muscle cramps, and lability of affect, but not necessarily mood. A diagnostic feature of ALS, typically not seen in other disorders, is the presence of hyperreflexia in segmental regions of muscle atrophy, unaccompanied by sensory disturbance.

At presentation, limb involvement occurs more often than bulbar involvement. Onset in the lower extremities is most common for familial ALS [Mulder et al 1986, Siddique 1991]. Various subtypes of ALS may be identified:

  • "Progressive bulbar palsy," which presents with speech disturbance and swallowing difficulties;
  • Limb-onset ALS;
  • Progressive muscular atrophy in which only lower motor neurons are involved; and
  • UMN-predominant ALS.

Regardless of initial symptoms, atrophy and weakness eventually spread to affect other muscles.

Oculomotor neurons are generally resistant to degeneration in ALS, but may be affected in individuals with a long disease course, especially when life span is extended by ventilatory support. Once all muscles of communication and expression are paralyzed, the individual is "locked in." In some instances, eye movements remain intact, allowing communication by way of special devices.

Death usually results from compromise of the respiratory muscles.

Frontotemporal involvement. Frontotemporal dementia (FTD) is a profound alteration in personality and social conduct characterized by loss of volition and insight, social disinhibition, and distractibility, with preservation of memory function [Neary et al 1998]. Common features include cognitive deficits in attention, abstraction, planning, and problem solving with preservation of perception and spatial functions. Language may be preferentially involved in individuals with progressive aphasia.

About 5% of individuals with ALS, regardless of family history, have FTD, which meets clinical criteria described by Neary et al [1998]. In families with dominantly inherited ALS/FTD, one member may have either FTD or ALS or both conditions [Hosler et al 2000].

From 30% to 50% of individuals with ALS have executive function impairment but do not meet the Neary criteria for dementia [Portet et al 2000, Lomen-Hoerth et al 2003]. In contrast to individuals with FTD, individuals with ALS may have more subtle deficits in executive function that may be missed with routine mental status examination. Formal neuropsychological testing can identify subtle alterations which may be masked by socially favorable traits such as empathy and optimism. These favorable traits have been known to specialists dealing with ALS and lead to considerable bonding between health care givers and persons with ALS. Affected individuals are also generally well-liked by the family, as social connections are maintained and their 'positive' attitudes are appreciated.

Individuals with ALS without frontotemporal dementia who exhibit executive dysfunction including deficits in verbal and nonverbal fluency and concept formation may do so early in the disease course. Executive dysfunction is seen more often in those with bulbar onset of disease [Schreiber et al 2005].

Additionally, white matter structural abnormalities may be present in the frontal and temporal lobes of individuals with ALS who do not demonstrate evidence of cognitive change [Abrahams et al 2005].

Conversely, Lomen-Hoerth et al [2002] report that clinical examination of 36 individuals with FTD and no family history of ALS or FTD revealed definite ALS in six and signs suggestive of ALS in another third.

Course. Sporadic ALS (SALS), or ALS in an individual with no family history of ALS, can be distinguished from familial ALS (FALS), or ALS in an individual from a family with at least one other blood relative affected with ALS. They are clinically similar. However, the mean age of onset in SALS is 56 years [Testa et al 2004], while the mean age of onset in FALS is approximately 46 years [Juneja et al 1997]. In general, individuals younger than age 55 years at onset of symptoms survive longer, regardless of gender [Magnus et al 2002]. Individuals who are diagnosed with ALS after age 80 years survive 1.7 years less than those with onset before age 80 [Forbes et al 2004]. Although respiratory function declines faster in ALS with bulbar onset, overall muscle weakness declines more slowly [Magnus et al 2002]. Progression in FALS may be significantly shorter or longer than in SALS and may be correlated with particular genetic mutations [Cudkowicz et al 1997, Juneja et al 1997].

Other. In SALS males are more likely to be affected than females at a rate of 1.3:1.

Penetrance of familial ALS is age and mutation dependent. Fifty percent of individuals with an SOD1 disease-causing mutation are symptomatic by age 46 years; 90% are symptomatic by age 70 years [Siddique 1991]. However, these percentages may be an overestimate because of ascertainment bias in families with high penetrance.

From 50% to 70% of individuals with one of two common FUS mutations are symptomatic by age 51 years, and more than 90% are symptomatic by age 71 years [Blair et al 2010].

Anticipation is not thought to be a feature, although intra- and interfamilial variability in age of onset and disease progression is common [Appelbaum et al 1992].

Establishing the Diagnosis of ALS

The diagnosis of ALS requires characteristic clinical features and findings on electrodiagnostic testing, as well as exclusion of other health conditions with related symptoms (see Differential Diagnosis of ALS).

Clinical features. The Escorial criteria [Brooks et al 2000] were developed to standardize diagnosis of ALS for research studies. While not all clinicians employ such stringent criteria, these criteria are increasingly used in everyday practice. They include:

  • The presence of:
    • Evidence of lower motor neuron (LMN) degeneration by clinical, electrophysiologic, or neuropathologic examination

      and
    • Evidence of upper motor neuron (UMN) degeneration by clinical examination

      and
    • Progressive spread of symptoms or signs within a region or to other regions, as determined by history or examination
  • Together with the absence of:
    • Electrophysiologic or pathologic evidence of other disease processes that could explain the signs of LMN and/or UMN degeneration

      and
    • Neuroimaging evidence of other disease processes that might explain the observed clinical and electrophysiologic signs.

Clinical evidence of UMN and LMN signs in four regions of the central nervous system (i.e., brain stem, cervical, thoracic, or lumbosacral spinal cord) can be obtained through careful history and physical and neurologic examinations.

The clinical diagnosis of ALS, without pathologic confirmation, may be categorized into various levels of certainty by clinical and laboratory assessment based on the Escorial criteria [Brooks et al 2000]:

  • Clinically definite ALS. The presence of UMN and LMN signs in three regions
  • Clinically definite familial, laboratory-supported ALS. Progressive upper and/or lower motor neuron signs in at least a single region (in the absence of another cause for the abnormal neurologic signs) in an individual with an identified ALS-causing mutation
  • Clinically probable ALS. The presence of UMN signs and LMN signs in at least two regions with some UMN signs necessarily rostral to (i.e., above) the LMN signs
  • Clinically probable, laboratory-supported ALS. Clinical signs of UMN and LMN dysfunction are in only one region, or UMN signs alone present in one region, and LMN signs defined by electromyogram (EMG) criteria present in at least two limbs
  • Clinically possible ALS. Clinical signs of UMN and LMN dysfunction found together in only one region, UMN signs found alone in two or more regions or LMN signs found rostral to UMN signs when the diagnosis of clinically probable, laboratory-supported ALS cannot be established.
  • Clinically suspected ALS. A pure LMN syndrome

Electrodiagnostic testing. Electromyogram (EMG) can demonstrate electrophysiologic evidence of LMN involvement in clinically affected or clinically uninvolved regions.

Pathology. A definitive diagnosis of ALS can be made based on brain stem and spinal cord pathology. Pathologic changes:

  • Degeneration and loss of the motor neurons in the anterior horns and in the motor nuclei of cranial nerves VII, X, and XI and most commonly the hypoglossal nucleus
  • Axonal loss with decreased myelin staining in the lateral and anterior corticospinal tracts. Degeneration of the corticobulbar and corticospinal tract is detected at the level of the internal capsule and cerebral peduncles in the midbrain.

Some individuals show mild degeneration of the mid-zone of the posterior sensory tracts, although sensory loss is usually not apparent during life.

Loss of Betz cells in the motor cortex has been documented but can be missed because of the paucity of Betz cells.

Histologic findings include presence of Lewy-like bodies and Bunina bodies in the cytoplasm of motor neurons. Ubiquinated bodies, described as skein-like inclusions, are virtually always present. SOD1-negative ALS pathology is characterized by ubiquitin-positive, tau-negative, and α-synuclein-negative cytoplasmic inclusions [Arai et al 2006].

Differential Diagnosis of ALS

Other hereditary and acquired conditions to be considered when establishing the diagnosis of ALS are discussed below [Traynor et al 2000].

Hereditary disorders include the following:

  • Spinal and bulbar muscular atrophy (SBMA, Kennedy disease) is an X-linked disorder, typically occurring in males only, characterized by proximal muscle weakness, muscle atrophy, and fasciculations. Affected males may have gynecomastia, testicular atrophy, and reduced fertility as a result of androgen insensitivity. SBMA can be distinguished clinically from non-familial ALS by the lack of upper motor neuron involvement, slow course, gynecomastia, and sensory involvement. Molecular genetic testing of the androgen receptor gene (AR) is diagnostic.
  • Spinal muscular atrophy (SMA) is an autosomal recessive disorder characterized by progressive degeneration and loss of anterior horn cells in the spinal cord and in some brain stem nuclei, resulting in proximal-greater-than-distal symmetric muscle weakness and atrophy (LMN involvement only). The onset of weakness ranges from before birth to adulthood. Molecular genetic testing of SMN identifies most individuals with spinal muscular atrophy caused by mutations in SMN.
  • ALS8 (also known as SMAIV or Finkel type SMA) could be considered in the context of normal SMN test results in an individual with adult-onset LMN disease with some UMN involvement. ALS8 is caused by mutations in VAPB and inherited in an autosomal dominant manner [Nishimura et al 2004].
  • Distal hereditary motor neuronopathy type VIIB, caused by mutations in DCTN1, is an early-adulthood-onset, slowly progressive autosomal dominant lower motor neuron disease with vocal cord involvement and preserved sensation [Puls et al 2003].
  • Primary lateral sclerosis (PLS) refers to the presence of slowly progressive, uncomplicated signs of upper motor neuron disease in persons in whom all other known causes of spasticity have been eliminated. Controversy exists as to whether PLS is a separate disorder or a subtype of ALS. Upper motor neuron-predominant ALS has little, often late, involvement of LMNs. Adult-onset PLS is a sporadic disorder, while at least a portion of juvenile-onset PLS is a recessive disorder. It may present as a progressive ascending paralysis first noted in infancy [Strong & Gordon 2005]. Mutations in at least one gene (ALS2) are associated with both ALS and PLS (see Table 2).
  • Hereditary spastic paraplegia (HSP) is characterized by insidiously progressive lower extremity weakness and spasticity. HSP is classified as "uncomplicated" if neurologic impairment is limited to progressive lower extremity spastic weakness, hypertonic urinary bladder, mild diminution of lower extremity vibration sensation, and, occasionally, joint position sensation. "Complicated" HSP is accompanied by other system involvement or other neurologic findings including seizures, dementia, amyotrophy, extrapyramidal disturbance, or peripheral neuropathy. Nonsyndromic or pure HSP does not reduce life span. HSP is genetically heterogeneous and can be inherited in an autosomal dominant, autosomal recessive, or X-linked manner.
  • Hexosaminadase A deficiency results in a group of neurodegenerative disorders caused by intralysosomal storage of the specific glycosphingolipid GM2 ganglioside. The juvenile, chronic, and adult-onset variants of hexosaminidase A deficiency are slowly progressive and have variable neurologic findings, including progressive dystonia, spinocerebellar degeneration, motor neuron disease, and, in some individuals with adult-onset disease, a bipolar form of psychosis.
  • Adult polyglucosan body disease is a slowly progressive disease of UMN and LMN dysfunction with distal sensory loss, early neurogenic bladder, cerebellar dysfunction, and cognitive impairment with onset after age 40 years [Tonin et al 1992, McDonald et al 1993]. Adult polyglucosan body disease is autosomal recessive and caused by mutations in GBE1, the gene encoding the glycogen branching enzyme.
  • BSCL2-related neurologic disorders. The spectrum of BSCL2-related neurologic disorders includes Silver syndrome and variants of Charcot-Marie-Tooth disease type 2, distal hereditary motor neuropathy type V, and spastic paraplegia 17 (SPG 17). Features of these disorders include slow disease progression, upper motor neuron involvement (i.e., gait disturbance with pyramidal signs ranging from mild to severe spasticity with hyperreflexia in the lower limbs and variable extensor plantar responses), lower motor neuron involvement (i.e., amyotrophy of the peroneal muscles and small muscles of the hand), abnormal vibration sense, and pes cavus and other foot deformities. Onset of symptoms ranges from the first to the seventh decade.
  • IBMPFD. Inclusion body myopathy associated with Paget disease of bone and/or frontotemporal dementia (IBMPFD) is characterized by adult-onset proximal and distal muscle weakness, early-onset Paget disease of bone, and premature frontotemporal dementia. IBMPFD is caused by mutations in VCP, the gene encoding transitional endoplasmic reticulum ATPase, which is associated with cellular activities including cell cycle control, membrane fusion, and the ubiquitin-proteosome degradation pathway.

Acquired disorders include cervical spine disease, brain stem or spinal cord tumors, thyroid disorders, lead poisoning, vitamin B12 deficiency, multiple sclerosis, paraneoplastic syndrome with occult cancer, motor neuropathies, myasthenia gravis, myasthenic syndrome, and inclusion body myositis.

Cervical spondylosis with cervical stenosis causing UMN signs in the legs and LMN signs in the arms should be considered as a differential diagnosis. Because cervical spondylosis is common, it is often identified in individuals who also have ALS. Electromyogram (EMG) and nerve conduction velocity (NCV) testing are performed to establish clinical evidence and extent of LMN disease.

To evaluate for other health conditions with related symptoms, the following may be performed:

  • Neuroimaging of brain and/or spinal cord
  • Blood studies, such as CBC; serum concentration of vitamin B12, lead, and TSH; and GM1 ganglioside autoantibodies (sometimes elevated in autoimmune motor neuropathies)
  • CSF examination to rule out infection or multiple sclerosis
  • Serum neuronal autoantibodies for paraneoplastic syndromes associated with occult cancer
  • Muscle and/or nerve biopsy as indicated
  • Testing for heavy metals if exposure is suspected

Note to clinicians: For a patient-specific ‘simultaneous consult’ related to amyotrophic lateral sclerosis, go to Image SimulConsult.jpg, an interactive diagnostic decision support software tool that provides differential diagnoses based on patient findings (registration or institutional access required).

Prevalence of ALS

The number of individuals newly diagnosed with ALS each year is 1-3:100,000.

The prevalence of individuals with ALS is roughly 4-8:100,000 [Traynor et al 1999] and is similar to the number of newly diagnosed individuals each year because people generally live only two to five years after the diagnosis of ALS is established.

The mean age of diagnosis in sporadic ALS is 56 years; individuals age 80 years and older have a standardized incidence of 10.2:100,000 in men and 6.1:100,000 in women [Forbes et al 2004].

Ethnic presentation of ALS worldwide is equal with the exception of the South Pacific (Guam) where the incidence of an ALS/parkinsonism/dementia complex is higher [Plato et al 2002, Waring et al 2004]. Although recent studies suggest a lower incidence in African populations, those need to be verified by population-based prospective studies.

Causes

Environmental (Acquired) Causes of ALS

Over the years a multitude of environmental exposures have been proposed as possible contributors to the cause of ALS, including mercury, manganese, and products used in farming (fertilizers, insecticides, herbicides), in addition to physical and dietary factors [Wicklund 2005].

Environmental exposures have been proposed as the explanation for an increased incidence of ALS in Gulf War veterans [Haley 2003, Horner et al 2003]. Further investigation is ongoing, and a registry has been developed for veterans with ALS [Kasarkis et al 2004]. Of note, veterans with a diagnosis of ALS are entitled to Veterans' Administration healthcare and disability benefits.

Heritable Causes

An estimated 10% of individuals with ALS have at least one other affected family member and are said to have familial ALS (FALS).

FALS can be categorized by mode of inheritance and subcategorized by specific gene or chromosomal locus.

Autosomal Dominant ALS (See Table 1)

Table 1. Molecular Genetics of Autosomal Dominant ALS

% of Individuals with FALSLocus Name (Gene Symbol 1)Disease NameProtein Name
20%ALS1 (SOD1)FALSSuperoxide dismutase (Cu-Zn)
RareALS3 (18q21)FALS
RareALS4 2 (SETX)Motor neuropathy with pyramidal featuresProbable helicase senataxin
~4%ALS6 (FUS/TLS)FALSRNA-binding protein FUS
RareALS7 (20p13)FALS
RareALS8 2 (VAPB)Finkel type SMA or SMA IVVesicle-associated membrane protein-associated protein B/C
Rare 3ALS9 (ANG)FALSAngiogenin
1%-4%ALS10 (TARDBP)TARDBP-related amyotrophic lateral sclerosisTAR DNA-binding protein 43
RareALS11 (FIG4)FALSPolyphosphoinositide phosphatase
23%-30%ALS/FTD 2 (C9orf72)C9FTD/ALSUncharacterized protein C9orf72
RareALS/FTD 2 (17q)Unknown
UnknownALS14 (VCP)FALSTransitional endoplasmic reticulum ATPase

See Amyotrophic Lateral Sclerosis: Phenotypic Series to view genes associated with this phenotype in OMIM.

1. Chromosomal locus provided only if gene is unknown

2. ALS-related motor neuron disorders with both UMN and LMN involvement

3. Possibly relevant to certain ethnic groups only

ALS1. SOD1 mutations account for only approximately 20% of all familial ALS and approximately 3% of sporadic ALS [Shaw et al 1998, Battistini et al 2005]. Simplex cases (i.e., those involving individuals with no family history of ALS) with SOD1 mutations are most likely the result of incomplete penetrance or incomplete family history information, although de novo mutations, observed in one family with the p.His80Arg mutation [Alexander et al 2002], provide another explanation [ALS Online Database].

Age of onset of ALS1 is poorly correlated with genotype; intrafamilial variability can be extensive [Cudkowicz et al 1997, Juneja et al 1997]. While particular mutations have been reported to be associated with earlier age of onset, sample sizes are too small to draw generalizations. For example:

  • Orrell et al [1997] reported a range of duration of 2.5 to 20 years in individuals with the p.Ile113Thr mutation and of two to 12 years in individuals with the p.Gly93Arg mutation.
  • The p.Ala4Val mutation, present in approximately 50% of all North American families with identifiable SOD1 mutations, is consistently associated with a rapid average disease course of one year [Juneja et al 1997].
  • On the opposite end of the spectrum are mutations that confer a significantly longer mean duration of at least 17 years, including p.Gly37Arg, p.Gly41Asp, p.His46Arg, and p.Glu100Lys [Cudkowicz et al 1997; Juneja et al 1997; Siddique & Brooks, unpublished observation].

Clinical presentation can occasionally be correlated with SOD1 mutations. Symptomatic persons with p.Ala4Val and p.Val148 mutations often have few UMN findings, which is the basis for the Escorial criterion that LMN findings in a person with an SOD1 mutation are sufficient to establish the diagnosis of ALS [Cudkowicz et al 1998].

Reduced penetrance has been documented, most notably with the p.Ile113Thr and p.Asp90Ala mutations [Khoris et al 2000].

Other issues with the p.Asp90Ala mutation:

  • Persons with the p.Asp90Ala mutation can present with ataxia, which can confuse the diagnosis initially.
  • The p.Asp90Ala mutation is noteworthy for its ethnic distribution and inheritance: individuals heterozygous for p.Asp90Ala from northern Sweden and Finland remain unaffected, while homozygotes develop ALS [Sjalander et al 1995]. Symptomatic heterozygotes have been identified in other populations, although they often have a slowly progressive course [Al-Chalabi et al 1998].
  • One family was identified as possibly having autosomal recessive ALS with a characteristic phenotype of lower limb onset, slow disease duration, and age of onset between 30 and 45 years. Affected individuals of this family are compound heterozygous for a p.Asp90Ala mutation and a p.Asp96Asn mutation; those family members who are heterozygous for one mutation only did not manifest the disease [Hand et al 2001].
  • Autosomal recessive inheritance of the p.Asp90Ala mutation has also been identified in three individuals of Italian ancestry with ALS [Conforti et al 2008] and one individual in Russia [Skvortsova et al 2001].

The cDNA and protein reference sequences for SOD1 are NM_000454.4 and NP_000445.1, respectively. By SOD1 convention, numbering does not begin with the initiating methionine codon, but rather the second codon for alanine. The amino acid numbering for mutations in this GeneReview follow this convention.

ALS3. In one large pedigree, presentation typical of ALS began in the legs for the majority of individuals; onset was age 45 years and duration was five years. No atypical features (e.g., pain, dementia, sensory loss, or cerebellar degeneration) were observed [Hand et al 2002].

ALS4 (juvenile-onset motor neuron disease with dominant inheritance and no bulbar involvement). ALS4 is associated with slowly progressive distal muscle weakness and atrophy with UMN signs, normal sensation, and absence of bulbar involvement [Rabin et al 1999]. De Jonghe et al [2002] identified three additional families of Belgian, Austrian, and English ancestry. Onset is in adolescence. The duration can be long, with some persons living a full life span. ALS4 is associated with mutations in SETX encoding the protein senataxin, which constitutes a DNA/RNA helicase domain with a possible role in RNA processing [Chen et al 2004]. Mutations in SETX have also been identified in individuals with ataxia and oculomotor apraxia type 2 (AOA2).

ALS6. Mutations in FUS (also known as TLS) have recently been identified in approximately 4% of SOD1-negative FALS cases, although screening of large FALS cohorts is necessary to establish exact prevalence. Kwiatkowski et al [2009] identified homozygous p.His517Gln (c.1551C>G) missense mutations in four individuals with ALS from a family of Cape Verdean origin. Their disease was characterized by proximal upper extremity weakness spreading to the lower extremities but not the bulbar region. The proband’s maternal grandparents were first cousins. Additional FUS screening revealed 13 FUS/TLS mutations in 17 families with FALS, whereas no FUS/TLS mutations were found in 293 individuals with SALS. The most common mutations were p.Arg521Cys and p.Arg521Gly, each identified in three families.

Further studies and analysis of pathology tissue from a p.Arg521Gly-positive individual showed diffuse ubiquitin positivity indicating cytoplasmic retention and aggregation of the mutant protein. FUS/TLS encodes a nucleoprotein that functions in DNA and RNA metabolism and has been implicated with tumorigenesis [Kwiatkowski et al 2009].

Independently Vance et al [2009] identified the p.Arg521Cys mutation in six members of a British kindred previously linked to chromosome 16. The same mutation was identified in four additional individuals in a cohort of 197 FALS index cases. Moreover, two novel missense mutations were identified in eight families.

Consistent with the observation of Kwiatkowski et al [2009], neuropathology on three individuals positive for FUS/TLS mutations showed FUS-immunoreactive cytoplasmic inclusions as well as predominant lower motor neuron disease. Clinical information on 20 individuals with ALS6 revealed even gender distribution, average age of onset of 44.5 years, and cervical onset in ten, lumbar onset in five, and bulbar onset in three. No affected individuals developed cognitive deficits.

The reference sequences for FUS are NM_004960.2 and NP_004951.1.

ALS7. Linkage has been identified in one pedigree with two of 15 affected sibs with an obligate heterozygote parent, raising the possibility of incomplete penetrance [Sapp et al 2003]. Clinical presentation was not reported.

ALS8. Known as SMAIV, or Finkel type SMA, ALS8 is characterized by primarily LMN findings, with UMN findings in some families. ALS8 is caused by mutations in VAPB, which encodes a protein that acts during ER-Golgi transport and secretion [Nishimura et al 2004]. The same p.Pro56Ser mutation was identified in one large family and six additional kindreds, all of whom have different courses (ALS8, late-onset SMA, and ALS with rapid progression). Haplotype analysis revealed that the p.Pro56Ser mutation is a founder mutation in individuals of Portuguese/Brazilian and African/Brazilian ancestry, a finding consistent with the Portuguese colonization of Brazil [Nishimura et al 2004].

The reference sequences for VAPB are NM_004738.3 and NP_004729.1.

ALS9. ALS9 has been reported in a small number of French, Italian, North American, and Northern European individuals with both sporadic and familial ALS [Greenway et al 2006, Wu et al 2007, Gellera et al 2008, Paubel et al 2008]. Affected individuals were reported to have typical ALS although a higher-than-expected proportion (60%) of individuals in the European cohort with ANG mutations had bulbar-onset disease.

  • The NP_001136.1:p.Arg145His (or Arg121His in the mature protein; also known as R121H) mutation was associated with rapid progression in a French individual.
  • The NP_001136.1:p.Lys41Ile (or Lys17Ile in the mature protein; also known as K17I) allelic variant (also found in healthy individuals, see following) was identified in a large Dutch kindred with FALS characterized by limb onset lower motor neuron-predominant disease with rapid to average progression. One affected individual had a five-year history of Parkinson disease prior to onset of ALS and symptoms suggestive of FTD.

The pathogenesis of ANG mutations remains to be established as the NP_001136.1:p.Ile70Val (or Ile46Val in the mature protein) and p.Lys41Ile mutations were also found in healthy individuals [Greenway et al 2006, Gellera et al 2008]. While mutations in ANG have not been robustly linked with ALS as a Mendelian disorder, they most likely constitute a risk factor in certain populations.

The reference sequences for ANG are NM_001145.4 and NP_001136.1.

ALS10 (TARDBP-related ALS). The phenotype of ALS10 is clinically indistinguishable from sporadic ALS and SOD1-positive FALS. TARDBP mutation frequency in FALS has been reported ranging from 0.6% [Sreedharan et al 2008] to 3.8% [Kabashi et al 2008] and identified in small numbers of Northern European, Australian, and Chinese individuals with FALS and SALS.

Spinal onset was reported in 77% of individuals with TARDBP mutations and lower motor neuron-predominant disease was seen in 39% [Kühnlein et al 2008]. FTD and/or cognitive impairments have not been reported in individuals with TARDBP mutations.

TARDBP encodes TDP-43, an RNA- and DNA-binding protein involved in regulation of gene expression and splicing. Interestingly, ubiquitinated TDP-43 inclusion bodies are found at autopsy in SOD1-negative FALS [Van Deerlin et al 2008] as well as in frontotemporal lobar degeneration (FTLD), further suggesting a clinical overlap between ALS and FTD. TDP-43 inclusions have been noted more widely; for example, they have been described in Alzheimer disease and other neurodegenerative disorders.

ALS11 (FIG4-related ALS). ALS11 was reported in five unrelated individuals of European descent diagnosed with probable or definite ALS, with two having a family history of the disorder [Chow et al 2009]. All had adult onset disease and showed prominent corticospinal tract findings. Nerve conduction velocity studies were normal; EMG studies showed some denervation [Chow et al 2009].

The five individuals were heterozygous for either a missense (1 person), splice site (2), or truncating (2) mutation in FIG4; all five mutations resulted in complete or highly significant loss of protein function [Chow et al 2009].

C9FTD/ALS (C9orf72-related ALS, ALS/FTD2). Individuals and family members with this syndrome have an FTD syndrome of behavioral change with relatively intact memory associated with signs of motor neuron disease. The associated FTD may be initially diagnosed as Alzheimer disease, mild cognitive impairment, or dementia with Lewy bodies [Murray et al 2011].

An expansion of a non-coding GGGGCC hexanucleotide repeat in C9orf72 was strongly associated with disease in a large FTD/ALS kindred. Further analysis of extended clinical series found the C9orf72 repeat expansion to be the most common genetic abnormality in both familial FTD (11.7%) and familial ALS (23.5%) [DeJesus-Hernandez et al 2011]. The repeat expansion leads to the loss of one alternatively spliced C9orf72 transcript and to formation of nuclear RNA foci, suggesting multiple disease mechanisms [DeJesus-Hernandez et al 2011].

In one study, all individuals with the C9orf72 repeat expansion presented with classic ALS with the exception of one person diagnosed with progressive muscular atrophy without upper motor neuron signs. Three individuals (18.8%) were diagnosed with a combined ALS/FTD phenotype. In the individuals with ALS with expanded repeats, 11/16 (68.8%) reported relatives with FTD or dementia, compared to only 61/213 (28.6%) of individuals with ALS without repeat expansions [DeJesus-Hernandez et al 2011]. On autopsy, affected individuals exhibited TDP-43 based pathology [DeJesus-Hernandez et al 2011].

Genetic heterogeneity exists, with ALS/FTD1 being linked to 9q21-q22 and ALS/FTD2 linked to 9p21.3-p13.2.

Wilhelmsen et al [2004] reported a family with ALS/FTD from San Francisco with α-synuclein and 4R/0N tau pathology linked to chromosome 17q. Clinical features include FTD, variable extrapyramidal symptoms, and prominent motor neuron disease. Family members reported frontal and anterior lobe dysfunction decades prior to onset of FTD or ALS. Three affected family members succumbed to ALS in their 50s or 60s within a few years of diagnosis. One presented with PSP-like syndrome in his 80s. Affected family members tested negative for mutations in MAPT, encoding the protein tau.

Pathologic findings include distinctive tau and α-synuclein inclusions. The insoluble tau protein inclusions consist predominantly of the 4R/0N isoform located almost exclusively in affected regions of the brain.

ALS14 (VCP-related ALS). Mutations in VCP, encoding valosin-containing protein, have been reported in an Italian family with autosomal dominant ALS [Johnson et al 2010]. All affected individuals displayed UMN and LMN signs, and EMG studies revealed denervation and chronic reinnervation changes. Five individuals followed a rapidly progressive course [Johnson et al 2010]. Mutations in VCP have been previously identified in families with inclusion body myopathy, Paget disease, and frontotemporal dementia (IBMPFD).

Autosomal Recessive ALS (See Table 2)

Table 2. Molecular Genetics of Autosomal Recessive ALS

% of Individuals with FALSLocus Name (Gene Symbol 1)Protein NameReferences
RareALS2 (ALS2)AlsinHentati et al [1994], Yang et al [2001]
RareALS5 (15q15.1-q21.1)Hentati et al [1998]
RareALS12 (OPTN)OptineurinMaruyama et al [2010]
RareSPG20 2 (SPG20)SpartinPatel et al [2002]

See Amyotrophic Lateral Sclerosis: Phenotypic Series to view genes associated with this phenotype in OMIM.

1. Chromosomal locus provided if gene is unknown

2. ALS-related motor neuron disorder with both UMN and LMN involvement

ALS2. Alsin-related disorders (ALS2-related disorders) involve retrograde degeneration of the upper motor neurons of the pyramidal tracts, which at onset appears as infantile ascending spastic paralysis (IAHSP); but all reported cases eventually end up as primary lateral sclerosis (JPLS). Other families also have lower motor neuron involvement resulting in a picture of upper motor neuron-predominant ALS.

ALS2-related disorders are characterized by onset during childhood (mean age at onset 6.5 years), spasticity of facial muscles, uncontrolled laughter, spastic dysarthria, spastic gait, inconstant moderate muscle atrophy, bladder dysfunction, and sensory disturbances; some individuals are bedridden by age 12 to 50 years.

ALS2 makes two transcripts of the protein by alternate splicing of a long form (resulting in juvenile-onset PLS) and a short form (resulting in juvenile-onset ALS) [Yang et al 2001]. Mutations in ALS2 have not been identified in individuals with adult-onset ALS [Hand et al 2003].

ALS5. Families with ALS5 from Tunisia, South Asia, and Germany have onset between ages eight and 18 years, with both UMN and LMN signs, fasciculations and atrophy of the tongue, and, occasionally, mild intellectual disability [Hentati et al 1998].

ALS12. ALS12 results from homozygous or heterozygous mutation in OPTN, encoding optineurin and mapping to chromosome 10p15-p14. Inheritance is autosomal recessive or autosomal dominant. Individuals with ALS12 were of Japanese descent and the result of consanguineous marriages. Age of onset ranged from the third to sixth decade. Most showed slow progression and extended disease duration before succumbing to respiratory failure [Maruyama et al 2010].

Optineurin has been shown to be involved in the pathogenesis of sporadic ALS and non-SOD1 familial ALS, indicating that these forms of ALS share a pathway that is distinct from that of SOD1-linked ALS [Deng et al 2011b].

Additional families exist in which neither mutations in ALS2 and OPTN nor linkage to 15q has been identified.

SPG20 (Troyer syndrome) is characterized by spastic paraparesis with dysarthria, distal amyotrophy, mild developmental delay, and short stature. Most affected children have delay in reaching the early developmental milestones (walking and talking), followed by slow deterioration in both gait and speech. Emotional lability and affective disorders such as inappropriate euphoria and/or crying are common. Mild cerebellar signs are common. The most severely affected individuals have choreoathetosis. It is caused by mutations in SPG20, encoding the protein spartin, which may be involved in endosomal trafficking.

X-Linked ALS (see Table 3)

Table 3. Molecular Genetics of X-linked ALS

% of Individuals with FALSLocus Name (Gene Symbol)Disease NameProtein Name
RareALS15 (UBQLN2)Amyotrophic lateral sclerosis 15, with or without frontotemporal dementiaUbiquilin-2

See Amyotrophic Lateral Sclerosis: Phenotypic Series to view genes associated with this phenotype in OMIM.

ALS15. Mutations in UBQLN2, which encodes the ubiquitin-like protein ubiquilin-2, cause X-linked dominant ALS and ALS/dementia [Deng et al 2011a].

Ubiquilin-2 pathology was reported in the spinal cords of individuals with ALS and in the brains of individuals with ALS/dementia with or without UBQLN2 mutations [Deng et al 2011a].

Ubiquilin-2 is a member of the ubiquilin family, which regulates the degradation of ubiquitinated proteins; functional analyses showed that mutations in UBQLN2 lead to an impairment of protein degradation [Deng et al 2011a]. These findings link abnormalities in ubiquilin-2 to defects in the protein degradation pathway, abnormal protein aggregation, and neurodegeneration, indicating a common pathogenic mechanism that can be exploited for therapeutic intervention [Deng et al 2011a].

Other. X-chromosome linkage was established in five families with adult-onset FALS in which no male-to-male transmission was evident. Clinically, these families had classic UMN and LMN involvement, with UMN signs typically preceding LMN signs. Male family members also had much earlier onset than females, often by age 20 years [Hong et al 1998].

Sporadic ALS

About 90% of ALS occurs in individuals with no family history of ALS; such individuals are said to have sporadic ALS (SALS). Note: True sporadic ALS needs to be distinguished from inherited ALS that occurs in simplex cases (i.e., affected individuals who have no family history of the disorder). For example, because of the decreased penetrance of some SOD1 mutations, an individual with an SOD1 mutation may sometimes be the only known affected family member (i.e., a simplex case), and thus be considered (incorrectly) a sporadic case.

Recent reports indicate a role of TARDBP mutations in what appeared to be sporadic ALS. Additional research is required to establish reduced penetrance, variable expressivity, and de novo mutation rate of both ANG and TARDBP mutations in SALS. These reports do not describe the extent of family history obtained to clearly establish that such individuals are simplex cases.

The etiology of sporadic ALS is unknown but is thought to be multifactorial. A combination of oxidative stress, glutamate excitotoxicity, mitochondrial dysfunction, inflammation, and apoptosis has repeatedly been proposed [Cleveland & Rothstein 2001] but not validated:

  • Mutations in the gene encoding vascular endothelial growth factor (VEGF) have also been proposed as playing a role in modifying ALS [Lambrechts et al 2003]. Although VEGF and related proteins probably have a biologic role in ALS, it is unlikely an etiologic role [Chen et al 2006].
  • Mutations in APOE, in particular the E*2 allele, may protect against the early onset of ALS [Li et al 2004].
  • Single-nucleotide polymorphisms (SNPs) in the paraoxonase gene cluster (PON) on chromosome 7q have been associated with sporadic ALS [Saeed et al 2006] in ethnically diverse populations. Serum paraoxonase is associated with high density lipoprotein (HDL), and polymorphisms in PON are associated with increased risk of coronary heart disease. PON enzymes are involved in the metabolism of intrinsic oxidized lipoid products and xenobiotics such as insecticides and nerve gas agents, as well as statin drugs.

Evaluation Strategy

Once the diagnosis of ALS has been established in an individual, the following approach can be used to determine the specific subtype of ALS to aid in discussions of prognosis and genetic counseling. Establishing the specific subtype of ALS in a given individual usually involves obtaining family history and performing molecular genetic testing.

Family history. A three-generation family history with attention to other relatives with neurologic signs and symptoms should be obtained. Documentation of relevant findings in relatives can be accomplished either through direct examination of those individuals or by review of their medical records including the results of molecular genetic testing, neuroimaging studies, and autopsy examinations.

Molecular genetic testing. Molecular genetic testing should be accompanied by formal genetic counseling and may include:

  • Gene-specific or sequential gene testing
    • SOD1 testing is appropriate in any individual with ALS who has another affected family member or an incomplete family history, including the early death of a close relative from any cause. Approximately 20% of individuals with FALS have ALS1 with an identified disease-causing mutation in SOD1. Interpretation of the significance of an SOD1 mutation regarding disease severity and progression depends on the specific mutation identified because of wide variability in genotype/phenotype correlations. Failure to detect an SOD1 mutation does not rule out FALS.

      Up to 3% of individuals with ALS with no family history of ALS have SOD1 mutations. Because data on penetrance of many mutations are limited, establishing the risk to other family members of developing clinical symptoms can be difficult.
    • SETX testing is appropriate in kindreds with adolescent-onset spinal muscular atrophy with pyramidal features.
    • VAPB testing should be pursued in the context of clinical symptoms of primarily adult-onset spinal muscular atrophy.
    • FUS/TLS, TARDBP, and ANG testing should be considered for SOD1-negative individuals with FALS.
    • ALS2 testing is appropriate for those with childhood-onset UMN-predominant ALS.
    • VCP testing should be considered for individuals with a family history of ALS with or without symptoms of inclusion body myopathy, Paget disease and/or frontotemporal dementia.
    • OPTN testing may be considered for individuals with a family history consistent with autosomal dominant or autosomal recessive inheritance, including simplex cases who do not have a mutation in more common ALS-related genes.

      OR
  • Multi-gene testing. Consider using a multi-gene ALS panel that includes a number of other genes associated with ALS.

    Note: Multi-gene panels vary by methods used and genes included; thus, the ability of a panel to detect a causative mutation or mutations in any given individual with ALS also varies.

Genetic Counseling

Genetic counseling is the process of providing individuals and families with information on the nature, inheritance, and implications of genetic disorders to help them make informed medical and personal decisions. The following section deals with genetic risk assessment and the use of family history and genetic testing to clarify genetic status for family members. This section is not meant to address all personal, cultural, or ethical issues that individuals may face or to substitute for consultation with a genetics professional. —ED.

Mode of Inheritance

Familial amyotrophic lateral sclerosis can be inherited in an autosomal dominant, autosomal recessive, or X-linked manner. Determination of the mode of inheritance is based on family history and molecular genetic testing.

Risk to Family Members — Autosomal Dominant ALS

Parents of a proband

Note: Although most individuals diagnosed with autosomal dominant ALS have an affected parent, the family history may appear to be negative because of failure to recognize the disorder in family members, early death of the parent before the onset of symptoms, or late onset or reduced penetrance of the disease in the affected parent.

Sibs of a proband

  • The risk to sibs depends on the genetic status of the proband's parents.
  • If one of the proband's parents has a mutant allele, the risk to the sibs of inheriting the mutant allele is 50%.
  • If neither parent has a mutant allele, the risk to sibs is low. Although no instances of germline mosaicism have been reported, it remains a possibility.

Offspring of a proband. Each child of an individual with autosomal dominant ALS has a 50% chance of inheriting the mutation.

Other family members of a proband. The risk to other family members depends on the status of the proband's parents. If a parent is affected, his or her family members may be at risk.

Risk to Family Members — Autosomal Recessive ALS

Parents of a proband

  • The parents of an affected individual are obligate heterozygotes and therefore carry a single copy of the disease-causing mutation.
  • Heterozygotes are asymptomatic.

Sibs of a proband

  • At conception, each sib has a 25% chance of inheriting the homozygous mutation and being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier.
  • Once an at-risk sib is known to be unaffected, the risk of his/her being a carrier is 2/3.
  • Heterozygotes are asymptomatic.

Offspring of a proband. The offspring of an individual with autosomal recessive ALS are obligate heterozygotes (carriers) for a disease-causing mutation.

Other family members of a proband. The sibs of obligate heterozygotes have a 50% chance of being heterozygotes.

Risk to Family Members — Empiric Risks

No data are available.

Related Genetic Counseling Issues

Testing of at-risk asymptomatic adults. Presymptomatic testing for mutations associated with ALS is controversial because of incomplete penetrance, inability to predict the age of onset, and the lack of preventive measures. Because of the individualized nature of predictive testing, consultation with a genetic counselor and a psychologist to obtain informed consent is recommended. At this time, no established testing protocol (as in, e.g., Huntington disease) exists, although establishment of such protocols has been suggested [Fanos et al 2004]. However, to err on the side of caution, testing centers often follow a similar protocol.

Testing of asymptomatic individuals younger than age 18 years who are at risk for adult-onset disorders for which no treatment exists is not considered appropriate, primarily because it negates the autonomy of the child with no compelling benefit. Further, concern exists regarding the potential adverse effects that such information may have on family dynamics, the risk of discrimination and stigmatization in the future, and the anxiety that such information may cause.

See also the National Society of Genetic Counselors position statement on genetic testing of minors for adult-onset conditions and the American Society of Human Genetics and American College of Medical Genetics points to consider: ethical, legal, and psychosocial implications of genetic testing in children and adolescents.

Individuals younger than age 18 years who are symptomatic usually benefit from having a specific diagnosis established.

DNA banking is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, mutations, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.

Prenatal Testing

If the disease-causing mutation(s) have been identified in the family, prenatal diagnosis for pregnancies at increased risk is possible by analysis of DNA extracted from fetal cells obtained by amniocentesis (usually performed at ~15-18 weeks’ gestation) or chorionic villus sampling (usually performed at ~10-12 weeks’ gestation). Such testing may be available through laboratories that offer either testing for the gene of interest or custom testing.

Note: Gestational age is expressed as menstrual weeks calculated either from the first day of the last normal menstrual period or by ultrasound measurements.

Performing prenatal testing for the disease-causing mutation prior to performing genetic testing on the parent (including presymptomatic genetic testing) could reveal the parent's gene status; therefore, genetic counseling is indicated in all considerations of prenatal testing for ALS.

Requests for prenatal testing for adult-onset conditions such as ALS are not common. Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. Although most centers would consider decisions about prenatal testing to be the choice of the parents, discussion of these issues is appropriate.

Preimplantation genetic diagnosis (PGD) may be an option for some families in which the disease-causing mutation(s) have been identified.

Resources

GeneReviews staff has selected the following disease-specific and/or umbrella support organizations and/or registries for the benefit of individuals with this disorder and their families. GeneReviews is not responsible for the information provided by other organizations. For information on selection criteria, click here.

  • Amyotrophic Lateral Sclerosis Association (ALS Association)
    27001 Agoura Road
    Suite 250
    Calabasas Hills CA 91301-5104
    Phone: 800-782-4747 (Toll-free Patient Services); 818-880-9007
    Fax: 818-880-9006
    Email: alsinfo@alsa-national.org
  • Amyotrophic Lateral Sclerosis Society of Canada
    3000 Steeles Avenue East
    Suite 200
    Markham Ontario L3R 4T9
    Canada
    Phone: 800-267-4257 (toll-free); 905-248-2052
    Fax: 905-248-2019
  • Les Turner ALS Foundation (Amyotrophic Lateral Sclerosis)
    5550 West Touhy Avenue
    Suite 302
    Skokie IL 60077-3254
    Phone: 888-257-1107 (toll-free); 847-679-3311
    Fax: 847-679-9109
    Email: info@lesturnerals.org
  • Muscular Dystrophy Association - USA (MDA-ALS Division)
    3300 East Sunrise Drive
    Tucson AZ 85718
    Phone: 800-344-4863 (toll-free); 800-572-1717 (toll-free)
    Email: mda@mdausa.org
  • National Library of Medicine Genetics Home Reference
  • NCBI Genes and Disease
  • National Amyotrophic Lateral Sclerosis (ALS) Registry
    Agency for Toxic Substances and Disease Registry
    4770 Buford Highway Northeast
    Atlanta GA 30341
    Phone: 800-232-4636
    Email: cdcinfo@cdc.gov

Management

Evaluations Following Initial Diagnosis

To establish the extent of disease in an individual diagnosed with amyotrophic lateral sclerosis (ALS), the following evaluations are recommended:

  • Electrophysiologic investigations. EMG/NCV (three extremities)
  • Laboratory workup. CSF analysis, muscle biopsy, 24-hour urine collection for heavy metals, blood work (including: CBC, comprehensive chemistry panel, GGT, B12, folate, RPR-syphilis, ANA8/RF, thyroid function, CK, serum protein electrophoresis (SPEP), urine protein electrophoresis (UPEP), immunofixation panel, quantitative immunoglobulin, qnti-GM1, serum Lyme AB, sed rate)
  • Radiologic. Head, C-spine, thoracic spine, and lumbar spine MRI
  • Neurologic. Physical examination, mental status, cranial nerves, motor examination, sensory examination, gait, reflexes
  • Neuropsychologic testing (if applicable) to assess cognitive impairment
  • Genetics consultation

Treatment of Manifestations

Treatment is palliative and many individuals benefit from care by a multidisciplinary team including: a neurologist, specially trained nurses, pulmonologist, speech therapist, physical therapist, occupational therapist, respiratory therapist, nutritionist, psychologist, social worker, and genetic counselor.

Data suggest that individuals under the care of such a team may have a better prognosis [van den Berg et al 2004, Andersen et al 2005]. The factors influencing survival include: age, vital capacity, fatigue, body strength, spasticity, household income, and depression [Paillisse et al 2005], most of which can be managed by the appropriate specialist in the multidisciplinary team.

Riluzole is the only currently FDA-approved drug for the treatment of ALS. Its mechanism of action is thought to be glutamate inhibition. Clinical trials have shown marginal slowing of disease progression in some but not all individuals, [Riviere et al 1998]. Riluzole is associated with elevation of serum alanine aminotransferase levels in 10% to 15% of treated individuals; in rare cases it may cause bone marrow depression [Bensimon & Doble 2004].

Oral secretions in individuals with bulbar symptoms can be reduced with tricylic antidepressants and anticholinergic agents, thus reducing the need for suctioning.

Pseudobulbar affect can be managed with antidepressants such as Nuedexta® (dextromethophan and quinidine).

Swallowing difficulties can be alleviated by thickening liquids and pureeing solid food, as well as eventually using a gastrostomy tube to help maintain caloric intake and hydration. Nutritional management, a prognostic factor for survival, has become a focus in the clinical setting.

Medications such as baclofen and benzodiazepines can help relieve spasticity and muscle cramps; however, weakness and lethargy are common side effects. Individualized moderate-intensity endurance-type exercises for the trunk and limbs may help to reduce spasticity [Ashworth et al 2004].

Low-tech (e.g., alphabet board) and high-tech (i.e., computer-assisted) devices can aid speech and communication. The recent development of the eye movement-controlled on-screen keyboard may enable communication for individuals without any remaining limb function.

Assistive devices, such as walkers or wheelchairs, can aid mobility; and others, such as bathroom installments, hospital bed, and Hoyer lift, can aid in activities of daily living at home.

Ventilatory assistance may include use of bilevel positive airway pressure (BIPAP), which has played an increasing role in preserving and prolonging quality of life in persons with ALS. In 1999, the American Academy of Neurology published norms recommending the initiation of noninvasive ventilation (NIV) in individuals with a theoretic forced vital capacity (FVC) less than 50% of predicted [Miller et al 1999]. Studies show that mean survival significantly increases when NIV is initiated prior to the onset of bulbar symptoms [Farrero et al 2005]. Therefore, evaluation by a pulmonologist should be undertaken before reduction of the forced vital capacity below 50%.

Although tracheostomy and ventilatory support can extend life span, affected individuals often decline these interventions [Albert et al 1999].

The tremendous psychological and social impact of ALS on both affected individuals and caregivers needs to be continually addressed [Goldstein et al 1998]. Hospice care, typically instituted once FVC is less than 30%, contributes to the individual’s comfort in the terminal stages.

Surveillance

Specialized multidisciplinary ALS clinic evaluations are suggested every three months.

  • Neurologic examination to establish the extent of weakness, atrophy, gait instability, involvement of fine motor and gross motor function and swallowing with attention to choking or coughing episodes and insensible aspiration manifesting as pneumonia
  • Pulmonary function tests
  • Nutritional status
  • PT/OT evaluation
  • Speech evaluation

Agents/Circumstances to Avoid

Patients and caregivers should be educated about safety precautions and environmental modifications for the home and at work.

Evaluation of Relatives at Risk

See Genetic Counseling for issues related to testing of at-risk relatives for genetic counseling purposes.

Therapies Under Investigation

Xaliproden slowed the rate of deterioration in FVC by 43% in individuals with ALS during Phase II safety and efficacy trials performed in France but did not improve functional or manual muscle testing scores [Lacomblez et al 2004]. Further investigations are needed.

Fornai et al [2008] reported a delay in disease progression in a small number of individuals with ALS taking a daily dose of lithium supplemental to riluzole. Additional research and clinical trials are needed to establish to neuroprotective effect of lithium.

Search ClinicalTrials.gov for access to information on clinical studies for a wide range of diseases and conditions.

Other

Individuals with ALS commonly supplement their diets with vitamin E, vitamin C, B vitamins, selenium, zinc, coenzyme Q10, and herbal preparations such as ginseng, gingko biloba, and Maharishi Amrit Kalesh [Cameron & Rosenfeld 2002]. In a Cochrane Review, Orrell et al [2007] summarized and evaluated 21 clinical trials of antioxidant therapies in various combinations including: vitamin E, high-dose coenzyme Q10, vitamin C, selenium, beta-carotene, N-acetylcysteine, L-methionine, and selegiline. In the majority of these studies, the sample size was not adequate for statistical evaluation. Although the antioxidants were well tolerated in many of the trials, significant differences in longevity, muscle strength, or functional rating scales over time were not identified.

References

Published Guidelines/Consensus Statements

  1. American Society of Human Genetics and American College of Medical Genetics. Points to consider: ethical, legal, and psychosocial implications of genetic testing in children and adolescents. Available online. 1995. Accessed 12-13-13. [PMC free article: PMC1801355] [PubMed: 7485175]
  2. McKinnon WC, Baty BJ, Bennett RL, Magee M, Neufeld-Kaiser WA, Peters KF, Sawyer JC, Schneider KA. Predisposition testing for late-onset disorders in adults: a position paper of the National Society of Genetic Counselors. JAMA. 1997;278:1217–20. [PubMed: 9333247]
  3. National Society of Genetic Counselors. Position statement on genetic testing of minors for adult-onset disorders. Available online. 2012. Accessed 12-13-13.

Literature Cited

  1. Abrahams S, Goldstein LH, Suckling J, Ng V, Simmons A, Chitnis X, Atkins L, Williams SC, Leigh PN. Frontotemporal white matter changes in amyotrophic lateral sclerosis. J Neurol. 2005;252:321–31. [PubMed: 15739047]
  2. Al-Chalabi A, Andersen PM, Chioza B, Shaw C, Sham PC, Robberecht W, Matthijs G, Camu W, Marklund SL, Forsgren L, Rouleau G, Laing NG, Hurse PV, Siddique T, Leigh PN, Powell JF. Recessive amyotrophic lateral sclerosis families with the D90A SOD1 mutation share a common founder: evidence for a linked protective factor. Hum Mol Genet. 1998;7:2045–50. [PubMed: 9817920]
  3. Albert SM, Murphy PL, Del Bene ML, Rowland LP. A prospective study of preferences and actual treatment choices in ALS. Neurology. 1999;53:278–83. [PubMed: 10430414]
  4. Alexander MD, Traynor BJ, Miller N, Corr B, Frost E, McQuaid S, Brett FM, Green A, Hardiman O. "True" sporadic ALS associated with a novel SOD-1 mutation. Ann Neurol. 2002;52:680–3. [PubMed: 12402272]
  5. Andersen PM, Borasio GD, Dengler R, Hardiman O, Kollewe K, Leigh PN, Pradat PF, Silani V, Tomik B. EFNS task force on management of amyotrophic lateral sclerosis: guidelines for diagnosing and clinical care of patients and relatives. Eur J Neurol. 2005;12:921–38. [PubMed: 16324086]
  6. Appelbaum JS, Roos RP, Salazar-Grueso EF, Buchman A, Iannaccone S, Glantz R, Siddique T, Maselli R. Intrafamilial heterogeneity in hereditary motor neuron disease. Neurology. 1992;42:1488–92. [PubMed: 1641141]
  7. Arai T, Hasegawa M, Akiyama H, Ikeda K, Nonaka T, Mori H, Mann D, Tsuchiya K, Yoshida M, Hashizume Y, Oda T. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun. 2006;351:602–11. [PubMed: 17084815]
  8. Ashworth NL, Satkunam LE, Deforge D. Treatment for spasticity in amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev. 2004;1:CD004156. [PubMed: 14974059]
  9. Battistini S, Giannini F, Greco G, Bibbo G, Ferrera L, Marini V, Causarano R, Casula M, Lando G, Patrosso MC, Caponnetto C, Origone P, Marocchi A, Del Corona A, Siciliano G, Carrera P, Mascia V, Giagheddu M, Carcassi C, Orru S, Garre C, Penco S. SOD1 mutations in amyotrophic lateral sclerosis. Results from a multicenter Italian study. J Neurol. 2005;252:782–8. [PubMed: 15789135]
  10. Bensimon G, Doble A. The tolerability of riluzole in the treatment of patients with amyotrophic lateral sclerosis. Expert Opin Drug Saf. 2004;3:525–34. [PubMed: 15500412]
  11. Blair IP, Williams KL, Warraich ST, Durnall JC, Thoeng AD, Manavis J, Blumbergs PC, Vucic S, Kiernan MC, Nicholson GA. FUS mutations in amyotrophic lateral sclerosis: clinical, pathological, neurophysiological and genetic analysis. J Neurol Neurosurg Psychiatry. 2010;81:639–45. [PubMed: 19965854]
  12. Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:293–9. [PubMed: 11464847]
  13. Cameron A, Rosenfeld J. Nutritional issues and supplements in amyotrophic lateral sclerosis and other neurodegenerative disorders. Curr Opin Clin Nutr Metab Care. 2002;5:631–43. [PubMed: 12394638]
  14. Chen W, Saeed M, Mao H, Siddique N, Dellefave L, Hung WY, Deng HX, Sufit RL, Heller SL, Haines JL, Pericak-Vance M, Siddique T. Lack of association of VEGF promoter polymorphisms with sporadic ALS. Neurology. 2006;67:508–10. [PubMed: 16894118]
  15. Chen YZ, Bennett CL, Huynh HM, Blair IP, Puls I, Irobi J, Dierick I, Abel A, Kennerson ML, Rabin BA, Nicholson GA, Auer-Grumbach M, Wagner K, De Jonghe P, Griffin JW, Fischbeck KH, Timmerman V, Cornblath DR, Chance PF. DNA/RNA helicase gene mutations in a form of juvenile amyotrophic lateral sclerosis (ALS4). Am J Hum Genet. 2004;74:1128–35. [PMC free article: PMC1182077] [PubMed: 15106121]
  16. Chow CY, Landers JE, Bergren SK, Sapp PC, Grant AE, Jones JM, Everett L, Lenk GM, McKenna-Yasek DM, Weisman LS, Figlewicz D, Brown RH, Meisler MH. Deleterious variants of FIG4, a phosphoinositide phosphatase, in patients with ALS. Am J Hum Genet. 2009;84:85–8. [PMC free article: PMC2668033] [PubMed: 19118816]
  17. Cleveland DW, Rothstein JD. From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nat Rev Neurosci. 2001;2:806–19. [PubMed: 11715057]
  18. Conforti FL, Sprovieri T, Mazzei R, Ungaro C, La Bella V, Tessitore A, Patitucci A, Magariello A, Gabriele AL, Tedeschi G, Simone IL, Majorana G, Valentino P, Condino F, Bono F, Monsurrò MR, Muglia M, Quattrone A. A novel Angiogenin gene mutation in a sporadic patient with amyotrophic lateral sclerosis from southern Italy. Neuromuscul Disord. 2008;18:68–70. [PubMed: 17703939]
  19. Cudkowicz ME, McKenna-Yasek D, Chen C, Hedley-Whyte ET, Brown RH. Limited corticospinal tract involvement in amyotrophic lateral sclerosis subjects with the A4V mutation in the copper/zinc superoxide dismutase gene. Ann Neurol. 1998;43:703–10. [PubMed: 9629839]
  20. Cudkowicz ME, McKenna-Yasek D, Sapp PE, Chin W, Geller B, Hayden DL, Schoenfeld DA, Hosler BA, Horvitz HR, Brown RH. Epidemiology of mutations in superoxide dismutase in amyotrophic lateral sclerosis. Ann Neurol. 1997;41:210–21. [PubMed: 9029070]
  21. DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, Nicholson AM, Finch NA, Flynn H, Adamson J, Kouri N, Wojtas A, Sengdy P, Hsiung GY, Karydas A, Seeley WW, Josephs KA, Coppola G, Geschwind DH, Wszolek ZK, Feldman H, Knopman DS, Petersen RC, Miller BL, Dickson DW, Boylan KB, Graff-Radford NR, Rademakers R. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72:245–56. [PMC free article: PMC3202986] [PubMed: 21944778]
  22. De Jonghe P, Auer-Grumbach M, Irobi J, Wagner K, Plecko B, Kennerson M, Zhu D, De Vriendt E, Van Gerwen V, Nicholson G, Hartung HP, Timmerman V. Autosomal dominant juvenile amyotrophic lateral sclerosis and distal hereditary motor neuronopathy with pyramidal tract signs: synonyms for the same disorder? Brain. 2002;125:1320–5. [PubMed: 12023320]
  23. Deng HX, Bigio EH, Zhai H, Fecto F, Ajroud K, Shi Y, Yan J, Mishra M, Ajroud-Driss S, Heller S, Sufit R, Siddique N, Mugnaini E, Siddique T. Differential involvement of optineurin in amyotrophic lateral sclerosis with or without SOD1 mutations. Arch Neurol. 2011b;68:1057–61. [PMC free article: PMC3357952] [PubMed: 21825243]
  24. Deng HX, Chen W, Hong ST, Boycott KM, Gorrie GH, Siddique N, Yang Y, Fecto F, Shi Y, Zhai H, Jiang H, Hirano M, Rampersaud E, Jansen GH, Donkervoort S, Bigio EH, Brooks BR, Ajroud K, Sufit RL, Haines JL, Mugnaini E, Pericak-Vance MA, Siddique T. Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. Nature. 2011a;477:211–5. [PMC free article: PMC3169705] [PubMed: 21857683]
  25. Fanos JH, Gelinas DF, Miller RG. "You have shown me my end": attitudes toward presymptomatic testing for familial amyotrophic lateral sclerosis. Am J Med Genet A. 2004;129A:248–53. [PubMed: 15326623]
  26. Farrero E, Prats E, Povedano M, Martinez-Matos JA, Manresa F, Escarrabill J. Survival in amyotrophic lateral sclerosis with home mechanical ventilation: the impact of systematic respiratory assessment and bulbar involvement. Chest. 2005;127:2132–8. [PubMed: 15947331]
  27. Forbes RB, Colville S, Swingler RJ. The epidemiology of amyotrophic lateral sclerosis (ALS/MND) in people aged 80 or over. Age Ageing. 2004;33:131–4. [PubMed: 14960427]
  28. Fornai F, Longone P, Cafaro L, Kastsiuchenka O, Ferrucci M, Manca ML, Lazzeri G, Spalloni A, Bellio N, Lenzi P, Modugno N, Siciliano G, Isidoro C, Murri L, Ruggieri S, Paparelli A. Lithium delays progression of amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A. 2008;105:2052–7. [PMC free article: PMC2538879] [PubMed: 18250315]
  29. Gellera C, Colombrita C, Ticozzi N, Castellotti B, Bragato C, Ratti A, Taroni F, Silani V. Identification of new ANG gene mutations in a large cohort of Italian patients with amyotrophic lateral sclerosis. Neurogenetics. 2008;9:33–40. [PubMed: 18087731]
  30. Goldstein LH, Adamson M, Jeffrey L, Down K, Barby T, Wilson C, Leigh PN. The psychological impact of MND on patients and carers. J Neurol Sci. 1998;160 Suppl 1:S114–21. [PubMed: 9851660]
  31. Greenway MJ, Andersen PM, Russ C, Ennis S, Cashman S, Donaghy C, Patterson V, Swingler R, Kieran D, Prehn J, Morrison KE, Green A, Acharya KR, Brown RH, Hardiman O. ANG mutations segregate with familial and 'sporadic' amyotrophic lateral sclerosis. Nat Genet. 2006;38:411–3. [PubMed: 16501576]
  32. Haley RW. Excess incidence of ALS in young Gulf War veterans. Neurology. 2003;61:750–6. [PubMed: 14504316]
  33. Hand CK, Devon RS, Gros-Louis F, Rochefort D, Khoris J, Meininger V, Bouchard JP, Camu W, Hayden MR, Rouleau GA. Mutation screening of the ALS2 gene in sporadic and familial amyotrophic lateral sclerosis. Arch Neurol. 2003;60:1768–71. [PubMed: 14676054]
  34. Hand CK, Khoris J, Salachas F, Gros-Louis F, Lopes AA, Mayeux-Portas V, Brewer CG, Brown RH, Meininger V, Camu W, Rouleau GA. A novel locus for familial amyotrophic lateral sclerosis, on chromosome 18q. Am J Hum Genet. 2002;70:251–6. [PMC free article: PMC384894] [PubMed: 11706389]
  35. Hand CK, Mayeux-Portas V, Khoris J, Briolotti V, Clavelou P, Camu W, Rouleau GA. Compound heterozygous D90A and D96N SOD1 mutations in a recessive amyotrophic lateral sclerosis family. Ann Neurol. 2001;49:267–71. [PubMed: 11220750]
  36. Hentati A, Bejaoui K, Pericak-Vance MA, Hentati F, Speer MC, Hung WY, Figlewicz DA, Haines J, Rimmler J, Ben Hamida C. et al. Linkage of recessive familial amyotrophic lateral sclerosis to chromosome 2q33-q35. Nat Genet. 1994;7:425–8. [PubMed: 7920663]
  37. Hentati A, Ouahchi K, Pericak-Vance MA, Nijhawan D, Ahmad A, Yang Y, Rimmler J, Hung W, Schlotter B, Ahmed A, Ben Hamida M, Hentati F, Siddique T. Linkage of a commoner form of recessive amyotrophic lateral sclerosis to chromosome 15q15-q22 markers. Neurogenetics. 1998;2:55–60. [PubMed: 9933301]
  38. Hong S, Brooks BR, Hung WY. et al. X-linked dominant locus for late-onset familial amyotrophic lateral sclerosis. Abstr Soc Neurosci. 1998;24:478.
  39. Horner RD, Kamins KG, Feussner JR, Grambow SC, Hoff-Lindquist J, Harati Y, Mitsumoto H, Pascuzzi R, Spencer PS, Tim R, Howard D, Smith TC, Ryan MA, Coffman CJ, Kasarskis EJ. Occurrence of amyotrophic lateral sclerosis among Gulf War veterans. Neurology. 2003;61:742–9. [PubMed: 14504315]
  40. Hosler BA, Siddique T, Sapp PC, Sailor W, Huang MC, Hossain A, Daube JR, Nance M, Fan C, Kaplan J, Hung WY, McKenna-Yasek D, Haines JL, Pericak-Vance MA, Horvitz HR, Brown RH. Linkage of familial amyotrophic lateral sclerosis with frontotemporal dementia to chromosome 9q21-q22. JAMA. 2000;284:1664–9. [PubMed: 11015796]
  41. Johnson JO, Mandrioli J, Benatar M, Abramzon Y, Van Deerlin VM, Trojanowski JQ, Gibbs JR, Brunetti M, Gronka S, Wuu J, Ding J, McCluskey L, Martinez-Lage M, Falcone D, Hernandez DG, Arepalli S, Chong S, Schymick JC, Rothstein J, Landi F, Wang YD, Calvo A, Mora G, Sabatelli M, Monsurrò MR, Battistini S, Salvi F, Spataro R, Sola P, Borghero G. ITALSGEN Consortium, Galassi G, Scholz SW, Taylor JP, Restagno G, Chiò A, Traynor BJ. (2010) Neuron. 2010;68:857–64. [PMC free article: PMC3032425] [PubMed: 21145000]
  42. Juneja T, Pericak-Vance MA, Laing NG, Dave S, Siddique T. Prognosis in familial amyotrophic lateral sclerosis: progression and survival in patients with glu100gly and ala4val mutations in Cu,Zn superoxide dismutase. Neurology. 1997;48:55–7. [PubMed: 9008494]
  43. Kabashi E, Valdmanis PN, Dion P, Spiegelman D, McConkey BJ, Vande Velde C, Bouchard JP, Lacomblez L, Pochigaeva K, Salachas F, Pradat PF, Camu W, Meininger V, Dupre N, Rouleau GA. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat Genet. 2008;40:572–4. [PubMed: 18372902]
  44. Kasarkis EJ, Dominic K, Oddone EZ. The National Registry of Veterans with Amyotrophic Lateral Sclerosis: Department of Veterans Affairs Cooperative Studies Program (CSP) #500a. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004;5 Suppl 1:129–32. [PubMed: 15512895]
  45. Khoris J, Moulard B, Briolotti V, Hayer M, Durieux A, Clavelou P, Malafosse A, Rouleau GA, Camu W. Coexistence of dominant and recessive familial amyotrophic lateral sclerosis with the D90A Cu,Zn superoxide dismutase mutation within the same country. Eur J Neurol. 2000;7:207–11. [PubMed: 10809943]
  46. Kühnlein P, Sperfeld AD, Vanmassenhove B, Van Deerlin V, Lee VM, Trojanowski JQ, Kretzschmar HA, Ludolph AC, Neumann M. Two German kindreds with familial amyotrophic lateral sclerosis due to TARDBP mutations. Arch Neurol. 2008;65:1185–9. [PMC free article: PMC2742976] [PubMed: 18779421]
  47. Kwiatkowski TJ Jr, Bosco DA, Leclerc AL, Tamrazian E, Vanderburg CR, Russ C, Davis A, Gilchrist J, Kasarskis EJ, Munsat T, Valdmanis P, Rouleau GA, Hosler BA, Cortelli P, de Jong PJ, Yoshinaga Y, Haines JL, Pericak-Vance MA, Yan J, Ticozzi N, Siddique T, McKenna-Yasek D, Sapp PC, Horvitz HR, Landers JE, Brown RH Jr. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science. 2009;323:1205–8. [PubMed: 19251627]
  48. Lacomblez L, Bensimon G, Douillet P, Doppler V, Salachas F, Meininger V. Xaliproden in amyotrophic lateral sclerosis: early clinical trials. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004;5:99–106. [PubMed: 15204011]
  49. Lambrechts D, Storkebaum E, Morimoto M, Del-Favero J, Desmet F, Marklund SL, Wyns S, Thijs V, Andersson J, van Marion I, Al-Chalabi A, Bornes S, Musson R, Hansen V, Beckman L, Adolfsson R, Pall HS, Prats H, Vermeire S, Rutgeerts P, Katayama S, Awata T, Leigh N, Lang-Lazdunski L, Dewerchin M, Shaw C, Moons L, Vlietinck R, Morrison KE, Robberecht W, Van Broeckhoven C, Collen D, Andersen PM, Carmeliet P. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet. 2003;34:383–94. [PubMed: 12847526]
  50. Li YJ, Pericak-Vance MA, Haines JL, Siddique N, McKenna-Yasek D, Hung WY, Sapp P, Allen CI, Chen W, Hosler B, Saunders AM, Dellefave LM, Brown RH, Siddique T. Apolipoprotein E is associated with age at onset of amyotrophic lateral sclerosis. Neurogenetics. 2004;5:209–13. [PubMed: 15657798]
  51. Lomen-Hoerth C, Anderson T, Miller B. The overlap of amyotrophic lateral sclerosis and frontotemporal dementia. Neurology. 2002;59:1077–9. [PubMed: 12370467]
  52. Lomen-Hoerth C, Murphy J, Langmore S, Kramer JH, Olney RK, Miller B. Are amyotrophic lateral sclerosis patients cognitively normal? Neurology. 2003;60:1094–7. [PubMed: 12682312]
  53. Magnus T, Beck M, Giess R, Puls I, Naumann M, Toyka KV. Disease progression in amyotrophic lateral sclerosis: predictors of survival. Muscle Nerve. 2002;25:709–14. [PubMed: 11994965]
  54. Maruyama H, Morino H, Ito H, Izumi Y, Kato H, Watanabe Y, Kinoshita Y, Kamada M, Nodera H, Suzuki H, Komure O, Matsuura S, Kobatake K, Morimoto N, Abe K, Suzuki N, Aoki M, Kawata A, Hirai T, Kato T, Ogasawara K, Hirano A, Takumi T, Kusaka H, Hagiwara K, Kaji R, Kawakami H. Mutations of optineurin in amyotrophic lateral sclerosis. Nature. 2010;465:223–6. [PubMed: 20428114]
  55. McDonald TD, Faust PL, Bruno C, DiMauro S, Goldman JE. Polyglucosan body disease simulating amyotrophic lateral sclerosis. Neurology. 1993;43:785–90. [PubMed: 8469341]
  56. Miller RG, Rosenberg JA, Gelinas DF, Mitsumoto H, Newman D, Sufit R, Borasio GD, Bradley WG, Bromberg MB, Brooks BR, Kasarskis EJ, Munsat TL, Oppenheimer EA. Practice parameter: the care of the patient with amyotrophic lateral sclerosis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology: ALS Practice Parameters Task Force. Neurology. 1999;52:1311–23. [PubMed: 10227612]
  57. Mulder DW, Kurland LT, Offord KP, Beard CM. Familial adult motor neuron disease: amyotrophic lateral sclerosis. Neurology. 1986;36:511–7. [PubMed: 3960325]
  58. Murray ME, DeJesus-Hernandez M, Rutherford NJ, Baker M, Duara R, Graff-Radford NR, Wszolek ZK, Ferman TJ, Josephs KA, Boylan KB, Rademakers R, Dickson DW. Clinical and neuropathologic heterogeneity of c9FTD/ALS associated with hexanucleotide repeat expansion in C9ORF72. Acta Neuropathol. 2011;122:673–90. [PMC free article: PMC3277860] [PubMed: 22083254]
  59. Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, Freedman M, Kertesz A, Robert PH, Albert M, Boone K, Miller BL, Cummings J, Benson DF. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology. 1998;51:1546–54. [PubMed: 9855500]
  60. Nishimura AL, Mitne-Neto M, Silva HC, Richieri-Costa A, Middleton S, Cascio D, Kok F, Oliveira JR, Gillingwater T, Webb J, Skehel P, Zatz M. A mutation in the vesicle-trafficking protein VAPB causes late-onset spinal muscular atrophy and amyotrophic lateral sclerosis. Am J Hum Genet. 2004;75:822–31. [PMC free article: PMC1182111] [PubMed: 15372378]
  61. Orrell RW, Habgood JJ, Gardiner I, King AW, Bowe FA, Hallewell RA, Marklund SL, Greenwood J, Lane RJ, deBelleroche J. Clinical and functional investigation of 10 missense mutations and a novel frameshift insertion mutation of the gene for copper-zinc superoxide dismutase in UK families with amyotrophic lateral sclerosis. Neurology. 1997;48:746–51. [PubMed: 9065559]
  62. Orrell RW, Lane RJM, Ross M. Antioxidant treatment for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev. 2007;24:CD002829. [PubMed: 17253482]
  63. Paillisse C, Lacomblez L, Dib M, Bensimon G, Garcia-Acosta S, Meininger V. Prognostic factors for survival in amyotrophic lateral sclerosis patients treated with riluzole. Amyotroph Lateral Scler Other Motor Neuron Disord. 2005;6:37–44. [PubMed: 16036424]
  64. Patel H, Cross H, Proukakis C, Hershberger R, Bork P, Ciccarelli FD, Patton MA, McKusick VA, Crosby AH. SPG20 is mutated in Troyer syndrome, an hereditary spastic paraplegia. Nat Genet. 2002;31:347–8. [PubMed: 12134148]
  65. Paubel A, Violette J, Amy M, Praline J, Meininger V, Camu W, Corcia P, Andres CR, Vourc'h P. French Amyotrophic Lateral Sclerosis (ALS) Study Group; Mutations of the ANG gene in French patients with sporadic amyotrophic lateral sclerosis. Arch Neurol. 2008;65:1333–6. [PubMed: 18852347]
  66. Plato CC, Galasko D, Garruto RM, Plato M, Gamst A, Craig UK, Torres JM, Wiederholt W. ALS and PDC of Guam: forty-year follow-up. Neurology. 2002;58:765–73. [PubMed: 11889241]
  67. Portet F, Martin K, Mazyad H, Jafari H, Gely-Nargeot C, Camu W (2000) Cognitive impairment in familial ALS with and without SOD1 mutations. Amyotroph Lateral Scler Other Motor Neuron Disord 1 S3:A90.
  68. Puls I, Jonnakuty C, LaMonte BH, Holzbaur EL, Tokito M, Mann E, Floeter MK, Bidus K, Drayna D, Oh SJ, Brown RH, Ludlow CL, Fischbeck KH. Mutant dynactin in motor neuron disease. Nat Genet. 2003;33:455–6. [PubMed: 12627231]
  69. Rabin BA, Griffin JW, Crain BJ, Scavina M, Chance PF, Cornblath DR. Autosomal dominant juvenile amyotrophic lateral sclerosis. Brain. 1999;122:1539–50. [PubMed: 10430837]
  70. Riviere M, Meininger V, Zeisser P, Munsat T. An analysis of extended survival in patients with amyotrophic lateral sclerosis treated with riluzole. Arch Neurol. 1998;55:526–8. [PubMed: 9561981]
  71. Saeed M, Siddique N, Hung WY, Usacheva E, Liu E, Sufit RL, Heller SL, Haines JL, Pericak-Vance M, Siddique T. Paraoxonase cluster polymorphisms are associated with sporadic ALS. Neurology. 2006;67:771–6. [PubMed: 16822964]
  72. Sapp PC, Hosler BA, McKenna-Yasek D, Chin W, Gann A, Genise H, Gorenstein J, Huang M, Sailer W, Scheffler M, Valesky M, Haines JL, Pericak-Vance M, Siddique T, Horvitz HR, Brown RH. Identification of two novel loci for dominantly inherited familial amyotrophic lateral sclerosis. Am J Hum Genet. 2003;73:397–403. [PMC free article: PMC1180377] [PubMed: 12858291]
  73. Schreiber H, Gaigalat T, Wiedemuth-Catrinescu U, Graf M, Uttner I, Muche R, Ludolph AC. Cognitive function in bulbar- and spinal-onset amyotrophic lateral sclerosis. A longitudinal study in 52 patients. J Neurol. 2005;252:772–81. [PubMed: 15742104]
  74. Shaw CE, Enayat ZE, Chioza BA, Al-Chalabi A, Radunovic A, Powell JF, Leigh PN. Mutations in all five exons of SOD-1 may cause ALS. Ann Neurol. 1998;43:390–4. [PubMed: 9506558]
  75. Siddique T. Molecular genetics of familial amyotrophic lateral sclerosis. Adv Neurol. 1991;56:227–31. [PubMed: 1853759]
  76. Sjalander A, Beckman G, Deng HX, Iqbal Z, Tainer JA, Siddique T. The D90A mutation results in a polymorphism of Cu,Zn superoxide dismutase that is prevalent in northern Sweden and Finland. Hum Mol Genet. 1995;4:1105–8. [PubMed: 7655469]
  77. Skvortsova VI, Limborska SA, Slominsky PA, Levitskaya NI, Levitsky GN, Shadrina MI, Kondratyeva EA. Sporadic ALS associated with the D90A Cu,Zn superoxide dismutase mutation in Russia. Eur J Neurol. 2001;8:167–72. [PubMed: 11284995]
  78. Sreedharan J, Blair IP, Tripathi VB, Hu X, Vance C, Rogelj B, Ackerley S, Durnall JC, Williams KL, Buratti E, Baralle F, de Belleroche J, Mitchell JD, Leigh PN, Al-Chalabi A, Miller CC, Nicholson G, Shaw CE. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science. 2008;319:1668–72. [PubMed: 18309045]
  79. Strong MJ, Gordon PH. Primary lateral sclerosis, hereditary spastic paraplegia and amyotrophic lateral sclerosis: discrete entities or spectrum? Amyotroph Lateral Scler Other Motor Neuron Disord. 2005;6:8–16. [PubMed: 16036421]
  80. Testa D, Lovati R, Ferrarini M, Salmoiraghi F, Filippini G. Survival of 793 patients with amyotrophic lateral sclerosis diagnosed over a 28-year period. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004;5:208–12. [PubMed: 15799548]
  81. Tonin P, Tomelleri G, Vio M, Rizzuto N. Polyglucosan body myopathy: a new case. Neuromuscul Disord. 1992;2:419–22. [PubMed: 1300190]
  82. Traynor BJ, Codd MB, Corr B, Forde C, Frost E, Hardiman O. Incidence and prevalence of ALS in Ireland, 1995-1997: a population- based study. Neurology. 1999;52:504–9. [PubMed: 10025778]
  83. Traynor BJ, Codd MB, Corr B, Forde C, Frost E, Hardiman O. Amyotrophic lateral sclerosis mimic syndromes: a population-based study. Arch Neurol. 2000;57:109–13. [PubMed: 10634456]
  84. Van Deerlin VM, Leverenz JB, Bekris LM, Bird TD, Yuan W, Elman LB, Clay D, Wood EM, Chen-Plotkin AS, Martinez-Lage M, Steinbart E, McCluskey L, Grossman M, Neumann M, Wu IL, Yang WS, Kalb R, Galasko DR, Montine TJ, Trojanowski JQ, Lee VM, Schellenberg GD, Yu CE. TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis. Lancet Neurol. 2008;7:409–16. [PMC free article: PMC3546119] [PubMed: 18396105]
  85. van den Berg JP, de Groot IJ, Joha BC, van Haelst JM, van Gorcom P, Kalmijn S. Development and implementation of the Dutch protocol for rehabilitative management in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004;5:226–9. [PubMed: 15799551]
  86. Vance C, Rogelj B, Hortobágyi T, De Vos KJ, Nishimura AL, Sreedharan J, Hu X, Smith B, Ruddy D, Wright P, Ganesalingam J, Williams KL, Tripathi V, Al-Saraj S, Al-Chalabi A, Leigh PN, Blair IP, Nicholson G, de Belleroche J, Gallo JM, Miller CC, Shaw CE. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science. 2009;323:1208–11. [PubMed: 19251628]
  87. Waring SC, Esteban-Santillan C, Reed DM, Craig UK, Labarthe DR, Petersen RC, Kurland LT. Incidence of amyotrophic lateral sclerosis and of the parkinsonism-dementia complex of Guam, 1950-1989. Neuroepidemiology. 2004;23:192–200. [PubMed: 15272222]
  88. Wicklund MP. Amyotrophic lateral sclerosis: possible role of environmental influences. Neurol Clin. 2005;23:461–84. [PubMed: 15757793]
  89. Wilhelmsen KC, Forman MS, Rosen HJ, Alving LI, Goldman J, Feiger J, Lee JV, Segall SK, Kramer JH, Lomen-Hoerth C, Rankin KP, Johnson J, Feiler HS, Weiner MW, Lee VM, Trojanowski JQ, Miller BL. 17q-linked frontotemporal dementia-amyotrophic lateral sclerosis without tau mutations with tau and alpha-synuclein inclusions. Arch Neurol. 2004;61:398–406. [PubMed: 15023818]
  90. Wu D, Yu W, Kishikawa H, Folkerth RD, Iafrate AJ, Shen Y, Xin W, Sims K, Hu GF. Angiogenin loss-of-function mutations in amyotrophic lateral sclerosis. Ann Neurol. 2007;62:609–17. [PMC free article: PMC2776820] [PubMed: 17886298]
  91. Yang Y, Hentati A, Deng HX, Dabbagh O, Sasaki T, Hirano M, Hung WY, Ouahchi K, Yan J, Azim AC, Cole N, Gascon G, Yagmour A, Ben-Hamida M, Pericak-Vance M, Hentati F, Siddique T. The gene encoding alsin, a protein with three guanine-nucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis. Nat Genet. 2001;29:160–5. [PubMed: 11586297]

Suggested Reading

  1. Andersen PM. The genetics of amyotrophic lateral sclerosis (ALS). Suppl Clin Neurophysiol. 2004;57:211–27. [PubMed: 16106621]
  2. Deng HX, Shi Y, Furukawa Y, Zhai H, Fu R, Liu E, Gorrie GH, Khan MS, Hung WY, Bigio EH, Lukas T, Dal Canto MC, O'Halloran TV, Siddique T. Conversion to the amyotrophic lateral sclerosis phenotype is associated with intermolecular linked insoluble aggregates of SOD1 in mitochondria. Proc Natl Acad Sci U S A. 2006;103:7142–7. [PMC free article: PMC1447523] [PubMed: 16636275]
  3. Furukawa Y, Fu R, Deng HX, Siddique T, O'Halloran TV. Disulfide cross-linked protein represents a significant fraction of ALS-associated Cu, Zn-superoxide dismutase aggregates in spinal cords of model mice. Proc Natl Acad Sci U S A. 2006;103:7148–53. [PMC free article: PMC1447524] [PubMed: 16636274]
  4. Gordon PH. Advances in clinical trials for amyotrophic lateral sclerosis. Curr Neurol Neurosci Rep. 2005;5:48–54. [PubMed: 15676108]
  5. Hand CK, Rouleau GA. Familial amyotrophic lateral sclerosis. Muscle Nerve. 2002;25:135–59. [PubMed: 11870681]
  6. Kunst CB. Complex genetics of amyotrophic lateral sclerosis. Am J Hum Genet. 2004;75:933–47. [PMC free article: PMC1182156] [PubMed: 15478096]
  7. McGeer EG, McGeer PL. Pharmacologic approaches to the treatment of amyotrophic lateral sclerosis. BioDrugs. 2005;19:31–7. [PubMed: 15691215]
  8. Siddique T, Lalani I. Genetic aspects of amyotrophic lateral sclerosis. Adv Neurol. 2002;88:21–32. [PubMed: 11908227]
  9. Vance C, Al-Chalabi A, Ruddy D, Smith BN, Hu X, Sreedharan J, Siddique T, Schelhaas HJ, Kusters B, Troost D, Baas F, de Jong V, Shaw CE. Familial amyotrophic lateral sclerosis with frontotemporal dementia is linked to a locus on chromosome 9p13.2-21.3. Brain. 2006;129:868–76. [PubMed: 16495328]

Chapter Notes

Author History

Lisa Dellefave, MS, CGC; University of Chicago (2000-2009)
Sandra Donkervoort, MS, CGC; Northwestern University Feinberg School of Medicine (2009-2012)
Mara Gaudette, MS; Northwestern University Medical School (2000-2006)
Lisa Kinsley, MS, CGC (2012-present)
Teepu Siddique, MD (2000-present)

Revision History

  • 31 May 2012 (me) Comprehensive update posted live
  • 28 July 2009 (me) Comprehensive update posted live
  • 21 November 2007 (cd) Revision: prenatal diagnosis for SETX mutations available clinically
  • 6 August 2007 (cd) Revision: testing available clinically for SETX-related amyotrophic lateral sclerosis
  • 23 June 2006 (ca) Comprehensive update posted to live Web site
  • 26 February 2004 (me) Comprehensive update posted to live Web site
  • 8 November 2001 (mg) Author revisions
  • 23 March 2001 (tk) Overview posted to live Web site
  • August 2000 (mg) Original submission
Copyright © 1993-2014, University of Washington, Seattle. All rights reserved.

For more information, see the GeneReviews Copyright Notice and Usage Disclaimer.

For questions regarding permissions: ude.wu@tssamda.

Bookshelf ID: NBK1450PMID: 20301623
PubReader format: click here to try

Views

  • PubReader
  • Print View
  • Cite this Page
  • Disable Glossary Links

Related information

  • MedGen
    Related information in MedGen
  • PMC
    PubMed Central citations
  • PubMed
    Links to pubmed

Related citations in PubMed

See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...